Kämmenen kalvokutistuman hoitostrategiat: satunnaistettu, kontrolloitu monikeskustutkimus
Phase 1
- Conditions
- MedDRA version: 19.1Level: PTClassification code 10013872Term: Dupuytren's contractureSystem Organ Class: 10028395 - Musculoskeletal and connective tissue disordersTherapeutic area: Diseases [C] - Skin and Connective Tissue Diseases [C17]
- Registration Number
- EUCTR2016-005215-41-FI
- Lead Sponsor
- Olli Leppänen
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Authorised-recruitment may be ongoing or finished
- Sex
- All
- Target Recruitment
- Not specified
Inclusion Criteria
Are the trial subjects under 18? no
Number of subjects for this age range:
F.1.2 Adults (18-64 years) yes
F.1.2.1 Number of subjects for this age range 211
F.1.3 Elderly (>=65 years) yes
F.1.3.1 Number of subjects for this age range 67
Exclusion Criteria
Not provided
Study & Design
- Study Type
- Interventional clinical trial of medicinal product
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method Main Objective: ;Secondary Objective: ;Primary end point(s):
- Secondary Outcome Measures
Name Time Method
Related Research Topics
Explore scientific publications, clinical data analysis, treatment approaches, and expert-compiled information related to the mechanisms and outcomes of this trial. Click any topic for comprehensive research insights.
What molecular mechanisms underlie Dupuytren's contracture and how do collagenase clostridium histolyticum, percutaneous needle fasciotomy, and limited fasciectomy modulate these pathways?
How does collagenase clostridium histolyticum compare to percutaneous needle fasciotomy and limited fasciectomy in terms of efficacy and cost-effectiveness for mild to moderate Dupuytren's contracture?
What biomarkers are associated with favorable outcomes in Dupuytren's contracture patients undergoing collagenase clostridium histolyticum, percutaneous needle fasciotomy, or limited fasciectomy treatments?
What are the known or potential adverse events associated with collagenase clostridium histolyticum, percutaneous needle fasciotomy, and limited fasciectomy in Dupuytren's contracture management?
Are there related compounds or combination approaches that enhance the therapeutic outcomes of collagenase clostridium histolyticum, percutaneous needle fasciotomy, or limited fasciectomy in Dupuytren's contracture treatment?